|
Accession number;02A0900960
|
| Title;Comparison the Effect of Beraprost Sodium with that of Limaprost Alfadex in Rat Neuropathic Intermittent Claudication Model. |
| Author;
LIU Y
(Hyogoidai Kaibougakudaini)
TAKENOBU YOSHIFUMI
(Onoyakuhinkogyo Minasesoken)
KAMANAKA YOSHIHISA
(Onoyakuhinkogyo Minasesoken)
MURAKATA SHIN'YA
(Onoyakuhinkogyo Minasesoken)
YUBA MIKIHIRO
(Onoyakuhinkogyo Minasesoken)
KATSUBE NOBUO
(Onoyakuhinkogyo Minasesoken)
OBATA TAKAAKI
(Onoyakuhinkogyo Minasesoken)
NOGUCHI KOICHI
(Hyogoidai Kaibougakudaini)
|
Journal Title;Japanese Pharmacology & Therapeutics
|
Journal Code:Z0947A
|
ISSN:0386-3603
|
|
VOL.30;NO.10;PAGE.875-880(2002)
|
| Figure&Table&Reference;FIG.2, TBL.1, REF.21 |
| Pub. Country;Japan |
| Language;Japanese |
| Abstract;Background: It is reported that Beraprost sodium, PGI2 analog is used for lumbar canal stenosis (LCS) patients. In the present study, effects of beraprost sodium on the walking distance and spinal cord blood flow (SCBF) in rat neuropathic intermittent claudication model were studied in comparison with limaprost alphadex, PGE1 analog that is launched for LCS. Methods: To induce neuropathic intermittent claudication, two pieces of silicon rubber were placed in the L4 and L6 lumbar epidural space in rats. Walking distance was measured using a treadmill apparatus. SCBF was measured using a laser-Doppler flowmeter. Results: Beraprost sodium showed no improvements in the walking distance and in SCBF at doses of 30-1000 .MU.g kg, p.o. * 2/day. In contrast, limaprost alphadex at 150 .MU.g/kg, p.o. * 2/day significantly improved the walking distance and SCBF. Conclusions: These data show that the efficiency of PGE1 on the walking distance and SCBF is more potent than that of PGI2 in rat neuropathic intermittent claudication model. (author abst.) |
|
|
|
Related Articles;
|
